تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Molina Healthcare Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $10.9B | |
|---|---|---|
| Revenue (ttm) | 42.1B | |
| Net income (ttm) | -48M | |
| EPS (ttm) | -$0.94 | |
| Shares out | 52.1M | |
| P/E (forward) | 18.9x | |
| Volume | 347,398 | |
| Beta | 0.78 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $27.77B | $31.97B | $34.07B | $40.65B | $45.43B | +13.1% |
| Gross profit | $3.28B | $3.93B | $4.33B | $4.74B | $4.08B | +5.6% |
| Operating income | $1.02B | $1.17B | $1.57B | $1.71B | $781.0M | -6.5% |
| Net income | $659.0M | $792.0M | $1.09B | $1.18B | $472.0M | -8.0% |
| EPS (diluted) | $11.25 | $13.55 | $18.77 | $20.42 | $8.92 | -5.6% |
| EBITDA | $1.13B | $1.35B | $1.74B | $1.89B | $976.0M | -3.5% |
| R&D | — | — | — | — | — | — |
| SG&A | $2.07B | $2.31B | $2.46B | $2.74B | $3.01B | +9.8% |
Recent company headlines from major financial publishers.
Our Base scenario projects a target value of $153.64, representing an implied return of -26.6% from $209.19 with an assigned probability of 55.0%. This scenario underwrites a measured post-trough recovery where state Medicaid rate adjustments gradually align with medical cost trends, allowing operating margins to normalize from FY2026 trough levels toward historical averages by FY2030. Discontinued product drags roll off into FY2027 as planned, and Medicare duals expansion offsets underlying Medicaid enrollment attrition. The scenario would be disconfirmed if Medicaid medical care ratios fail to improve in upcoming fiscal quarters or if individual exchange losses persist, which would become visible through state rate filings and quarterly statutory disclosures.
Our Bull scenario projects Potential value of $188.58, representing an implied return of -9.9% from $209.19 with an assigned probability of 20.0%. This upside pathway requires accelerated state rate updates that rapidly restore Medicaid pretax margins above targeted thresholds, complete elimination of exchange underwriting deficits, and aggressive top-line compounding driven by major state contract procurement wins and dual-eligible outperformance. This scenario would be disconfirmed if state procurement renewal awards are delayed, if competing commercial plans undercut pricing, or if medical cost trends accelerate in high-acuity populations.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.7% | $166 | $170 | $174 | $179 | $185 |
| 8.2% | $156 | $159 | $163 | $167 | $171 |
| 8.7% | $148 | $151 | $154 | $157 | $161 |
| 9.2% | $141 | $143 | $146 | $148 | $151 |
| 9.7% | $134 | $136 | $139 | $141 | $143 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
